Astrazeneca Plc ADR (AZN)

$88.61 +0.93 (1.06%)
Market Cap 271.93B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 19.49
Forward PE 19.45
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 4,514,400
Avg Vol 4,991,258
Day's Range N/A - N/A
Shares Out 3.10B
Stochastic %K 91%
Beta 0.34
Analysts Strong Sell
Price Target $89.96

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
HedgeAlerts
HedgeAlerts Nov. 14 at 8:07 AM
Hedge Alert Live - Protect Your Portfolio Contract: $AZN $87.50 Put · NOV 21, 2025 Exp Entry Price: $0.70 - $0.85 Exit Price Target: $1.27 Profit Margin: +82% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
EmSol
EmSol Nov. 13 at 4:34 PM
$GILD oh yay see you at $150 and $110 for $AZN
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
jmig
jmig Nov. 12 at 5:10 PM
$AZN sub 90 buying opportunity
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Nov. 12 at 10:28 AM
$TGTX $AZN
0 · Reply
TendyWendy
TendyWendy Nov. 11 at 6:15 PM
$AZN 100$ next
0 · Reply
EmSol
EmSol Nov. 11 at 6:02 PM
$AZN it’s coming fast
0 · Reply
DefenseMania
DefenseMania Nov. 10 at 3:00 PM
$PFE $LLY $AZN https://finance.yahoo.com/news/pfizer-wins-obesity-drug-prize-142520909.html
0 · Reply
Quantumup
Quantumup Nov. 10 at 12:15 PM
Chardan Capital⬆️ $MNPR's PT to $100 from $85, reiterated at a Buy, and said, MNPR (Buy): PT to $100. Data at AASLD Shows ALXN1840 Improves Copper Balance $AZN On 9 November 2025, the company presented new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) meeting. The presented data mirrored that in the 17 September 2025 Letter to the Editor, published in The Journal of Hepatology, in which the authors provide a new analysis of data showing that ALXN1840 rapidly improves copper balance in Wilson disease patients.
0 · Reply
BioRich
BioRich Nov. 10 at 5:06 AM
$AZN Congrats on the Codadutide data. 40% Effective size is significant for Fibrosis. Wow. The added beauty is hopefully this new data will finally allow folks pumping Pemvi ($ALT) that they continue to push false narratives trying to fool people into buying $ALT to cover their losses. But it's not about $ALT, it's about $AZN. Nice data and look forward to future updates. Cheers!
0 · Reply
Latest News on AZN
Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

Nov 14, 2025, 7:06 AM EST - 1 hour ago

Health Rounds: Lilly blood thinner tops AstraZeneca's for heart procedure patients with diabetes

LLY

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

Nov 11, 2025, 7:45 AM EST - 3 days ago

FTSE 100 hits record high as job market data weakens pound; AstraZeneca shines

AstraZeneca hits record high, cements lead as UK's biggest stock

Nov 11, 2025, 3:42 AM EST - 3 days ago

AstraZeneca hits record high, cements lead as UK's biggest stock

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Nov 10, 2025, 1:39 PM EST - 3 days ago

AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Nov 9, 2025, 4:33 PM EST - 4 days ago

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Nov 7, 2025, 9:00 AM EST - 6 days ago

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:26 PM EST - 7 days ago

AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript

AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

Nov 6, 2025, 3:28 PM EST - 7 days ago

AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

AstraZeneca's 9M and Q3 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 8 days ago

AstraZeneca's 9M and Q3 2025 Financial Results

AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO

Nov 6, 2025, 4:12 AM EST - 8 days ago

AstraZeneca's strong U.S. ties reflect Trump's policy of equalization, says CEO

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

Nov 6, 2025, 2:39 AM EST - 8 days ago

AstraZeneca Revenue Climbs on Pipeline Strength, U.S. Price Deal

AstraZeneca beats third-quarter revenue and profit expectations

Nov 6, 2025, 2:04 AM EST - 8 days ago

AstraZeneca beats third-quarter revenue and profit expectations

AstraZeneca wins shareholder backing for NYSE listing in US pivot

Nov 3, 2025, 11:11 AM EST - 10 days ago

AstraZeneca wins shareholder backing for NYSE listing in US pivot

AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US

Nov 3, 2025, 11:06 AM EST - 10 days ago

AstraZeneca wins shareholder backing for NYSE listing as drugmaker pivots to US

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

Nov 3, 2025, 9:17 AM EST - 10 days ago

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer

Oct 31, 2025, 1:19 AM EDT - 14 days ago

FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer

BP

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

Oct 24, 2025, 4:51 AM EDT - 21 days ago

AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

AstraZeneca hails major breakthroughs with breast-cancer drugs

Oct 20, 2025, 6:53 AM EDT - 25 days ago

AstraZeneca hails major breakthroughs with breast-cancer drugs

AstraZeneca's Datroway extends survival in aggressive breast cancer

Oct 19, 2025, 2:32 AM EDT - 26 days ago

AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

Oct 18, 2025, 10:33 AM EDT - 26 days ago

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

Oct 17, 2025, 4:17 PM EDT - 27 days ago

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

Oct 17, 2025, 4:08 PM EDT - 27 days ago

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

AMGN

AstraZeneca unveils expanded manufacturing facility in Texas

Oct 15, 2025, 10:00 AM EDT - 4 weeks ago

AstraZeneca unveils expanded manufacturing facility in Texas

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Oct 13, 2025, 7:00 AM EDT - 4 weeks ago

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

Oct 12, 2025, 9:25 AM EDT - 4 weeks ago

Banquets and billions: How AstraZeneca sealed a US medicine deal with Trump

Trump announces drug-pricing deal with pharma giant

Oct 10, 2025, 7:30 PM EDT - 4 weeks ago

Trump announces drug-pricing deal with pharma giant

Trump reaches deal with AstraZeneca to lower U.S. drug prices

Oct 10, 2025, 6:30 PM EDT - 4 weeks ago

Trump reaches deal with AstraZeneca to lower U.S. drug prices

AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.

Oct 10, 2025, 6:23 PM EDT - 4 weeks ago

AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising.

Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices

Oct 10, 2025, 6:17 PM EDT - 4 weeks ago

Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices

TrumpRx makes more drug pricing moves and strikes a deal with AstraZeneca

Oct 10, 2025, 6:05 PM EDT - 4 weeks ago

TrumpRx makes more drug pricing moves and strikes a deal with AstraZeneca

Trump says AstraZeneca to offer drugs to US at discounted prices

Oct 10, 2025, 5:54 PM EDT - 4 weeks ago

Trump says AstraZeneca to offer drugs to US at discounted prices

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

Oct 10, 2025, 3:45 PM EDT - 4 weeks ago

AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter

Oct 10, 2025, 3:45 PM EDT - 4 weeks ago

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices, according to a person familiar with the matter

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

Oct 10, 2025, 2:53 PM EDT - 4 weeks ago

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

Oct 10, 2025, 10:15 AM EDT - 4 weeks ago

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

LLY

AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump

Oct 9, 2025, 12:32 PM EDT - 5 weeks ago

AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

Oct 9, 2025, 12:30 PM EDT - 5 weeks ago

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery

Oct 9, 2025, 6:00 AM EDT - 5 weeks ago

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

Oct 7, 2025, 7:00 AM EDT - 5 weeks ago

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

AstraZeneca's Baxdrostat meets main goal in high blood pressure study

Oct 7, 2025, 2:14 AM EDT - 5 weeks ago

AstraZeneca's Baxdrostat meets main goal in high blood pressure study

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 5 weeks ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG BIIB BMY GILD

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Oct 6, 2025, 8:04 AM EDT - 5 weeks ago

AstraZeneca signs up to $555 million deal with US-based Algen to develop gene therapies

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

Oct 6, 2025, 8:00 AM EDT - 5 weeks ago

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

Oct 6, 2025, 5:25 AM EDT - 5 weeks ago

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

AstraZeneca's Datroway boosts survival in advanced breast cancer trial

Oct 6, 2025, 2:57 AM EDT - 5 weeks ago

AstraZeneca's Datroway boosts survival in advanced breast cancer trial

Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated

Oct 3, 2025, 4:20 PM EDT - 5 weeks ago

Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated

LLY NVO PFE

AstraZeneca shares leap with FDA set to review drug to treat breast cancer

Oct 1, 2025, 10:54 AM EDT - 6 weeks ago

AstraZeneca shares leap with FDA set to review drug to treat breast cancer

CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

Oct 1, 2025, 1:30 AM EDT - 6 weeks ago

CNBC's UK Exchange newsletter: AstraZeneca gets a shot on Wall Street

AstraZeneca's US listing may pull other firms from London in its wake

Sep 30, 2025, 10:29 AM EDT - 6 weeks ago

AstraZeneca's US listing may pull other firms from London in its wake

AstraZeneca plans to list on NYSE, but will remain in the U.K.

Sep 29, 2025, 2:52 PM EDT - 6 weeks ago

AstraZeneca plans to list on NYSE, but will remain in the U.K.

HedgeAlerts
HedgeAlerts Nov. 14 at 8:07 AM
Hedge Alert Live - Protect Your Portfolio Contract: $AZN $87.50 Put · NOV 21, 2025 Exp Entry Price: $0.70 - $0.85 Exit Price Target: $1.27 Profit Margin: +82% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
EmSol
EmSol Nov. 13 at 4:34 PM
$GILD oh yay see you at $150 and $110 for $AZN
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:28 PM
$RADX TRP Target Selection & Drug Design Summit 2026 (February 24–26, Boston, MA) - Over three days, experts from Novartis, Bayer, Abdera, Radiopharm Theranostics, AstraZeneca, OncoOne, PentixaPharm, Bicycle Therapeutics, Université Laval $BAYRY $NVS $BCYC $AZN
0 · Reply
jmig
jmig Nov. 12 at 5:10 PM
$AZN sub 90 buying opportunity
0 · Reply
Uncle_Baby_Billy
Uncle_Baby_Billy Nov. 12 at 10:28 AM
$TGTX $AZN
0 · Reply
TendyWendy
TendyWendy Nov. 11 at 6:15 PM
$AZN 100$ next
0 · Reply
EmSol
EmSol Nov. 11 at 6:02 PM
$AZN it’s coming fast
0 · Reply
DefenseMania
DefenseMania Nov. 10 at 3:00 PM
$PFE $LLY $AZN https://finance.yahoo.com/news/pfizer-wins-obesity-drug-prize-142520909.html
0 · Reply
Quantumup
Quantumup Nov. 10 at 12:15 PM
Chardan Capital⬆️ $MNPR's PT to $100 from $85, reiterated at a Buy, and said, MNPR (Buy): PT to $100. Data at AASLD Shows ALXN1840 Improves Copper Balance $AZN On 9 November 2025, the company presented new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) meeting. The presented data mirrored that in the 17 September 2025 Letter to the Editor, published in The Journal of Hepatology, in which the authors provide a new analysis of data showing that ALXN1840 rapidly improves copper balance in Wilson disease patients.
0 · Reply
BioRich
BioRich Nov. 10 at 5:06 AM
$AZN Congrats on the Codadutide data. 40% Effective size is significant for Fibrosis. Wow. The added beauty is hopefully this new data will finally allow folks pumping Pemvi ($ALT) that they continue to push false narratives trying to fool people into buying $ALT to cover their losses. But it's not about $ALT, it's about $AZN. Nice data and look forward to future updates. Cheers!
0 · Reply
DownUpSideway
DownUpSideway Nov. 10 at 4:39 AM
$AZN wow this is down like 3 points overnight?
1 · Reply
Wolly99
Wolly99 Nov. 10 at 1:50 AM
$ALT I thought $AZN had shelved cotadutide (GLP-1/GCGR agonist) but they just presented results and they’re….objectively awful! 48W WL if 5-10%. No stat sign MASH response, fibrosis went up(?!) in the low dose compared to biopsy but improved in high dose. ALT and AST were unimpressive as well. Not great for AZN. Can’t imagine they continue cotadutide.
8 · Reply
AlertsAndNews
AlertsAndNews Nov. 9 at 10:49 PM
$AZN Headline here earlier today. Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial "Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025"
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 9 at 9:21 AM
💎 LiquidTheta® Live Actionable Trade Asset: $AZN Contracts: $AZN January 15, 2027 $85 Calls Scale in: $9.03- $11.04 Scale out: $35.13-$60.23 Profit Potential : 66% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Chipwars
Chipwars Nov. 7 at 3:57 PM
$AZN $AAPL. Lifeboats to be in, during a storm.
0 · Reply
DefenseMania
DefenseMania Nov. 7 at 2:15 PM
$AZN huge news for GILD this am $PFE $MRK $BMY
0 · Reply
Quantumup
Quantumup Nov. 7 at 12:00 PM
Jefferies⬆️ $AUPH to Buy-$21 from Hold-$10 $GSK $AZN $RHHBY $AMGN Jefferies said in its note: We are upgrading AUPH to Buy based on AUPH's commercial performance w/ lead asset Lupkynis, which has led to a strong balance sheet and (+) cash flow -- notably, supported by disciplined spend. Also, we see AUPH's BAFF/APRIL inh aritinercept, which has shown promising initial healthy volunteer clinical data, as under-the-radar w/ derisked MOA, and we expect it to get more attention as AUPH reveals clin dev path in early '26. Upgrade to Buy w/ PT $21.
0 · Reply
opmankc
opmankc Nov. 6 at 6:00 PM
$MTSR maybe $AZN should join in the fun with $MRK
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 5:54 PM
$AZN crushed Q3 expectations — broad strength across its key drug lineup 💪 Core earnings and revenue both topped estimates, with Tagrisso, Imfinzi, and Farxiga driving solid, diversified growth across the portfolio. Full breakdown of AstraZeneca’s Q3 beat here 👉 https://www.zacks.com/stock/news/2787058/azn-q3-earnings-top-estimates-sales-rise-as-most-key-drugs-outperform?cid=sm-stocktwits-2-2787058-teaser-19883&ADID=SYND_STOCKTWITS_TWEET_2_2787058_TEASER_19883
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 5:45 PM
$TVTX News just posted on FSGS study. (Strange time of day to release news). Data is fantastic. Feel like FSGS approval is a slam dunk. $LLY and $NVS are likely watching very closely, if not already accumulating. Hope that kicks $AZN and $JNJ into higher gear on $TVTX
2 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 4:54 PM
$AZN beats Q3 earnings estimates — what's fueling the growth? 🚀 📈 Core earnings rose 14% YoY on a reported basis 💊 Key drugs Tagrisso, Imfinzi, and Farxiga outperformed 📊 Total revenues up 12% on a reported basis, driven by product and alliance sales Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2787058/azn-q3-earnings-top-estimates-sales-rise-as-most-key-drugs-outperform?cid=sm-stocktwits-2-2787058-body-19870&ADID=SYND_STOCKTWITS_TWEET_2_2787058_BODY_19870
0 · Reply
DeadInvestor
DeadInvestor Nov. 6 at 4:09 PM
$TVTX Then, in Feb, $NVS or $LLY announce acquisition, in the $60.00 to $75.00 range (with $AZN and $JNJ watching )
0 · Reply